Answers are grounded in this paper and cite their sources.
Among patients with stage III epithelial ovarian cancer, the addition of HIPEC to interval cytoreductive surgery resulted in longer recurrence-free survival and overall survival than surgery alone and did not result in higher rates of side effects. (Funded by the Dutch Cancer Society; ClinicalTrials.gov number, NCT00426257 ; EudraCT number, 2006-003466-34 .).
No takes yet. Share an insight, caveat, or question.
Driel et al. (2018) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: